Published date:Sep 27 2023

Journal Title: Sudan Journal of Medical Sciences

Issue title: Sudan JMS: Volume 18 (2023), Issue No. 3

Pages:284 - 290

DOI: 10.18502/sjms.v18i3.14083

Dalya M. M. AbdelmagedFaculty of Medicine, Al Neelain University, Khartoum, Sudan

Carol A. AvilaUniversidad de Carabobo, Valencia, Venezuela

Abubaker A MohamedSharifFaculty of Medicine, University of Khartoum, Khartoum, Sudan

Isra Bdraldein Salih MohammedIsrabdr1995@gmail.comFaculty of Medicine, University of Khartoum, Khartoum, Sudan

A 95-year-old man came with violaceous nodular skin lesions of the left shin. The lesions were not painful or pruritic but progressed rapidly over the 3 months. Fever, night sweats, weight loss, and other systemic symptoms were absent. Shave biopsy of the lesion revealed the cells negative for CD20 but positive for BCL2, BCL6, FOX-P1, and CD10. PET/CT showed high uptake in the left leg and a sizeable hypermetabolic lymph node in the left pelvis. The patient was started on rituximab treatment as a single agent. This report highlights some of the diagnostic and treatment difficulties in CD20 negative lymphomas and the importance of a multidisciplinary approach in those cases.

Keywords: diffuse large B-cell lymphoma, leg type (DLBCL-LT), primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT), positron emission tomography/computed tomography (PET/CT), cluster of differentiation (CD), B-cell lymphoma 2 (BCL2), B-cell lymphoma 6 (BCL6), Forkhead box P1 (FOX-P1), cmyelocytomatosis oncogene product (C-MYC), multiple myeloma oncogene 1 (MUM1), Epstein-Barr virus (EBV)-encoded RNA 1 (EBER-1)

[1] Thomas, V., Dobson, R., & Mennel, R. (2011). Primary cutaneous large B-cell lymphoma, leg type. Proc, 24(4), 350– 353. https://doi.org/10.1080/08998280.2011.11928757

[2] Hristov, A. C. (2012). Primary cutaneous diffuse large B-cell lymphoma, leg type: Diagnostic considerations. Archives of Pathology & Laboratory Medicine, 136(8), 876–881. https://doi.org/10.5858/arpa.2012-0195-RA

[3] BioLegend.[Internet]. San Diego, CA: BioLegend; c2021 [cited 2021 Oct 20]. Available from: https://www.biolegend.com/

[4] Biosciences, B. D. [Internet]. San Jose, CA: BD Biosciences; c2021 [cited 2021 Oct 20]. Available from: https://www.bdbiosciences.com/

[5] TreeStar Inc. [Internet]. Ashland, OR: TreeStar Inc; c2021 [cited 2021 Oct 20]. Available from: https://www.flowjo.com/

[6] Willemze, R., Cerroni, L., Kempf, W., Berti, E., Facchetti, F., Swerdlow, S. H., & Jaffe, E. S. (2019, April 18). The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood, 133(16), 1703–1714. https://doi.org/10.1182/blood-2018- 11-881268

[7] Sica, A., Vitiello, P., Caccavale, S., Sagnelli, C., Calogero, A., Doraro, C. A., Pastore, F., Ciardiello, F., Argenziano, G., Reginelli, A., Cappabianca, S., Franco, R., & Ronchi, A. (2020). Primary Cutaneous DLBCL Non-GCB Type: Challenges of a Rare Case. Open Medicine (Warsaw), 15, 119–125. https://doi.org/10.1515/med-2020-0018

[8] Katchi, T., & Liu, D. (2017, February 7). Diagnosis and treatment of CD20 negative B cell lymphomas. Biomarker Research, 5(1), 5. https://doi.org/10.1186/s40364-017- 0088-5

[9] Pham-Ledard, A., Prochazkova-Carlotti, M., Andrique, L., Cappellen, D., Vergier, B., Martinez, F., Grange, F., Petrella, T., Beylot-Barry, M., & Merlio, J. P. (2014, March). Multiple genetic alterations in primary cutaneous large Bcell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma. Modern Pathology, 27(3), 402– 411. https://doi.org/10.1038/modpathol.2013.156